OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates	519
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action	265
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2	200
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic	193
Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases	169
Protein-based antigen presentation platforms for nanoparticle vaccines	126
The use of viral vectors in vaccine development	118
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19	117
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents	109
Access to and equitable distribution of COVID-19 vaccine in low-income countries	97
Extended interval BNT162b2 vaccination enhances peak antibody generation	86
Vaccines for human fungal diseases: close but still a long way to go	86
Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation	84
Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel	81
Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines	75
Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees	68
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy	68
Is new dengue vaccine efficacy data a relief or cause for concern?	64
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models	63
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza	62
Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice	55
A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus	54
Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis	53
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate	53
Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination	51

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge	50
A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection	50
Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report	49
SARS-CoV-2 structural features may explain limited neutralizing-antibody responses	49
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets	48
Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters	47
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates	47
“World in motion” – emulsion adjuvants rising to meet the pandemic challenges	47
Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge	47
Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells	46
SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses	45
The future of Japanese encephalitis vaccination: expert recommendations for achieving and maintaining optimal JE control	43
Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants	41
Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters	41
Current status of monkeypox vaccines	39
A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses	39
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease	39
Challenges and developments in universal vaccine design against SARS-CoV-2 variants	39
Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases	39
The shot, the message, and the messenger: COVID-19 vaccine acceptance in Latin America	39